Subscribe
shutterstock_1414222322_chris_redan
Chris Redan / Shutterstock.com
6 April 2021BiotechnologyClare Roskell and Samantha Moodie

EPO’s new examination guidelines: what you need to know

A new edition of the European Patent Office (EPO) Guidelines for Examination came into force on March 1, 2021. Relevant to life sciences, this edition includes a new subsection detailing EPO practice with respect to the interpretation of terms relating to amino or nucleic acid sequences, as well as a new section on the examination of claims to antibodies.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
Pharma patent filings rise at EPO amid pandemic
5 April 2022   Patent applications in Europe reached record levels during 2021 amid the COVID-19 pandemic, according to a new report by the European Patent Office.
Europe
EPO Enlarged Board of Appeal issues G 2/21 decision
28 March 2023   Board provides guidance on evidence submitted after patent filing date | Eagerly awaited decision confirms what’s needed to prove a certain effect.
Europe
EPO launches Unitary Patent dashboard revealing daily take-up figures
25 July 2023   Interactive statistics chart shows more than 5,000 requests for unitary effect | Data can be filtered by country, language and technology sector.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Europe
Pharma patent filings rise at EPO amid pandemic
5 April 2022   Patent applications in Europe reached record levels during 2021 amid the COVID-19 pandemic, according to a new report by the European Patent Office.
Europe
EPO Enlarged Board of Appeal issues G 2/21 decision
28 March 2023   Board provides guidance on evidence submitted after patent filing date | Eagerly awaited decision confirms what’s needed to prove a certain effect.
Europe
EPO launches Unitary Patent dashboard revealing daily take-up figures
25 July 2023   Interactive statistics chart shows more than 5,000 requests for unitary effect | Data can be filtered by country, language and technology sector.

More on this story

Europe
Pharma patent filings rise at EPO amid pandemic
5 April 2022   Patent applications in Europe reached record levels during 2021 amid the COVID-19 pandemic, according to a new report by the European Patent Office.
Europe
EPO Enlarged Board of Appeal issues G 2/21 decision
28 March 2023   Board provides guidance on evidence submitted after patent filing date | Eagerly awaited decision confirms what’s needed to prove a certain effect.
Europe
EPO launches Unitary Patent dashboard revealing daily take-up figures
25 July 2023   Interactive statistics chart shows more than 5,000 requests for unitary effect | Data can be filtered by country, language and technology sector.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Attorney v examiner: Navigating patenting's AI tools ‘arms race’
Panitch Schwarze brings in molecular biologist
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
‘Don’t stifle UK AI innovation’: King's speech on AI Act prompts warnings
Most active firms at UPC revealed in report on court’s first year
FTC supports USPTO terminal disclaimer plan amid opposition